Opinion|Videos|December 3, 2024
Addressing Challenges in Accessing Traditional STI Screening Options
Author(s)Kameelah Phillips, MD, FACOG, NCMP
The panelist discusses how asymptomatic sexually transmitted infections (STIs) can silently impact overall health, emphasizing the importance of comprehensive screening and education, particularly for less known STIs like trichomoniasis and Mycoplasma genitalium, while exploring how newer testing methods like nucleic acid amplification testing (NAAT) can address challenges in traditional screening access and improve patient care.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- In what ways can asymptomatic STIs impact overall health, and why is screening important?
- How can health care providers effectively raise awareness about less commonly known STIs like trichomoniasis and Mycoplasma genitalium?
- What challenges do patients face when accessing traditional STI screenings testing, and how can these be addressed?
- How does the use of newer screening methods like NAAT impact patient access to necessary screenings?
Advertisement
Related to this article
In the premiere episode of Mind, Body, & the Pause, Soma Mandal, MD, is joined by Manisha Parulekar, MD, and Jocelyn Carlo, MD, FACOG, to discuss the stages of the menopause transition.
Mental health, bias, and trauma shape sexual health visits, and histories should assess function, not just risk, according to Sameena Rahman, MD.
This FAQ summarizes a Special Report discussion on off-label testosterone dosing, application, cost, and lab monitoring in women.
This FAQ summarizes a Special Report discussion on how two experts decide who is a candidate for testosterone therapy in women, from symptoms and context to hormone state vs age.
This FAQ summarizes a Special Report discussion of what the evidence does and does not establish about testosterone therapy in women.
Kanchi Chadha, MD, FACOG, MSCP, supports reconsidering MHT boxed warnings but says the FDA cited no study behind the change.
HRSA will award up to $1 million to a single organization to update the Women's Preventive Services Guidelines through the new WISH program.
Real-world data show maternal RSVpreF vaccination was 82% effective against infant RSV LRTI hospitalization through 3 months.
Advertisement
Advertisement
Trending on Contemporary OB/GYN
1
Centers for Medicare, Medicaid Services includes AMA's obstetric codes in 2027 fee schedule
2
FAQ: How is off-label testosterone dosed and monitored in women?
3
Q&A: Soma Mandal, MD, MSCP, on FDA boxed warning removals for MHT
4
FAQ: Who is a candidate for testosterone therapy in women?
5